
Our vision is to be the accepted PAIONeer in sedation and anesthesia; helping advance patient care.
PAION announces submission of New Drug Application for remimazolam by its partner Mundipharma in Japan
PAION announces that NMPA accepts submission of New Drug Application for remimazolam by Chinese licensee Yichang Humanwell
PAION AG raises EUR 5.2 million in private placement